NF1

2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

SpringWorks Therapeutics
1 program
1
MirdametinibPhase 1/2Small Molecule1 trial
Active Trials
NCT06159166RecruitingEst. Nov 2028
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
ImlygicPhase 11 trial
Active Trials
NCT07102394Recruiting10Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
SpringWorks TherapeuticsMirdametinib
AmgenImlygic

Clinical Trials (2)

Total enrollment: 10 patients across 2 trials

NCT06159166SpringWorks TherapeuticsMirdametinib

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

Start: Feb 2024Est. completion: Nov 2028
Phase 1/2Recruiting
NCT07102394AmgenImlygic

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Start: Feb 2026Est. completion: Dec 202710 patients
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 10 patients
2 companies competing in this space